Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Advanced Squamous NSCLC with HRAS Mutations
2017-004822-13Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tipifarnib in Pulmonary squamous cell carcinoma (2 arms), sponsored by Fundación GECP. Primary endpoint: Objective response rate by RECIST 1.1. Started Jun 2018; status: active.
02
Drugs
tipifarnib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2017-004822-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004822-13.